Chen, Wei-Chih Hu, Gangqing Hazlehurst, Lori A
Published in
Current opinion in pharmacology
The bone marrow microenvironment (BMM) provides input via production of cytokines, chemokines, extracellular matrixes in the context of lower oxygen levels that influences self-renewal, survival, differentiation, progression, and therapeutic resistance of multiple myeloma and leukemic cells. Within the context of the BMM, tumor cells are supported ...
Sitkovsky, Michail V
Published in
Current opinion in pharmacology
The anti-hypoxia-A2-Adenosinergic immunotherapies of cancer emerged as the only available now approach to enable the tumor rejection in those progressing cancer patients that are refractory to all other current treatments. Several different classes of drugs are offered to inhibit the Hypoxia-HIF-1alpha-mediated and extracellular adenosine-A2A adeno...
Sek, Kevin Kats, Lev M Darcy, Phillip K Beavis, Paul A
Published in
Current opinion in pharmacology
Adoptive cellular therapy involves the ex vivo expansion of immune cells, conventionally T cells, before reinfusion back to the patient. Variations in adoptive cellular therapy include transduction of a patient's T cells with either a transgenic T cell receptor or chimeric antigen receptor (CAR) to recognize a defined tumor antigen. Given that aden...
Halpin-Veszeleiova, Katarina Hatfield, Stephen M
Published in
Current opinion in pharmacology
The promising results of the first in-human clinical study using A2AR antagonists for treatment of renal cell carcinoma highlight two decades of research into the hypoxia-A2-adenosinergic pathway. Importantly, clinical responses have been observed in patients who previously progressed on anti-PD-1/PDL-1 therapy, emphasizing the clinical importance ...
Helms, Rachel S Powell, Jonathan D
Published in
Current opinion in pharmacology
Adenosine signaling through A2AR serves as a negative regulator of the immune system. Unique to this suppressive pathway is its ability to impact numerous stromal and immune cells. Additionally, tumors exhibit elevated concentrations of adenosine further advancing the pathway's potential as a powerful target for activating anti-tumor immunity. The ...
Roh, Meejeon Wainwright, Derek A Wu, Jennifer D Wan, Yong Zhang, Bin
Published in
Current opinion in pharmacology
CD73 (ecto-5'-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response. However, tumors take advantage of the CD73-mediated adenosinergic mechanism...
Bae, Seyeon Zeng, Steven Park-Min, Kyung-Hyun
Published in
Current opinion in pharmacology
Osteoclasts are bone-resorbing cells that play an essential role in the remodeling of bone under physiological conditions and numerous pathological conditions, such as osteoporosis, bone metastasis, and inflammatory bone erosion. Nuclear receptors are crucial to various physiological processes, including metabolism, development and inflammation, an...
Ray, Evan C
Published in
Current opinion in pharmacology
Robust clinical data indicate that inhibitors of the sodium/glucose cotransporter 2 (SGLT2) dramatically improve clinical outcomes in diabetes, especially heart failure and progression of kidney disease. Factors that may contribute to these findings include: 1) improved glycemic control, 2) diuresis and reduced extracellular fluid volume, 3) reduce...
Huang, Jumin Jiang, Zebo Wang, Yuwei Fan, Xiaoqing Cai, Jun Yao, Xiaojun Liu, Liang Huang, Jun He, Jianxing Xie, Chun
...
Published in
Current opinion in pharmacology
Immune checkpoint blockade therapies that target CTLA-4 and PD-1/PD-L1 have ushered in a new era of cancer treatment. Nevertheless, a significant proportion of patients demonstrated primary or acquired resistance. Harnessing gut microbiota has been an emerging novel therapeutic strategy to overcome resistance. Here we summarized the current researc...
Glaría, Estibaliz Letelier, Nicole A Valledor, Annabel F
Published in
Current opinion in pharmacology
Liver X receptors (LXRs) are transcription factors from the nuclear receptor family that can be pharmacologically activated by high-affinity agonists. LXR activation exerts a combination of metabolic and anti-inflammatory actions that result in the modulation of immune responses and in the amelioration of inflammatory disorders. In addition, LXR ag...